ICAM1 and cholangiocarcinoma: We further explored the biological activities of ICAM1 ADCs on the tumor microenvironment of a patient-derived xenograft (PDX) of CCA via transcriptomic profiling, providing biomechanistic insights of ICAM1 ADC treatment.